Expansion
At WnsFeild Pharmaceuticals, our commitment to innovation and patient care extends to our strategic growth. We are not just expanding; we are building for the future of healthcare. Our next major capital investment is focused on the establishment of a cutting-edge Sterile Injectable Section for Steroids.
This expansion aligns with global market trends and our vision to address the growing demand for specialized, high-potency parenteral products. The new facility will be a pinnacle of modern pharmaceutical engineering, incorporating the latest in aseptic processing and containment technologies.
Key Features of the Planned Expansion:
-
Aseptic Fill-Finish Operations: This new section will feature fully isolated, aseptic fill-finish lines for both liquid and lyophilized (freeze-dried) injectable products. This will allow for the production of highly stable and sensitive formulations, including those containing steroids and hormones.
-
Dedicated & Segregated Suites: To ensure zero risk of cross-contamination, this facility will be a completely segregated unit with dedicated HVAC and pressure control systems. The design will follow a unidirectional workflow for personnel and materials, from entry to product exit, a critical requirement for handling high-potency active pharmaceutical ingredients (APIs).
-
Modular and Scalable Design: The facility is being designed with a modular approach, allowing for future scalability and the seamless integration of new technologies, such as robotic process automation (RPA) for vial handling and inspection. This ensures we can quickly adapt to changing market demands without a complete site overhaul.
-
Advanced Sterilization & Containment: We will utilize state-of-the-art sterilization techniques, including terminal sterilization where feasible, and implement robust containment strategies to protect both product integrity and personnel safety. This includes high-efficiency HEPA filtration and validated Clean-in-Place (CIP) and Sterilize-in-Place (SIP) systems.
-
Data Integrity & Digitalization: Our new facility will be a "smart" facility. We are incorporating a Distributed Control System (DCS) and real-time monitoring to ensure critical process parameters (CPPs) and critical quality attributes (CQAs) are maintained. This enhances our quality by design (QbD) approach and provides a robust Corrective and Preventive Action (CAPA) framework.
This strategic expansion represents a significant investment in our capacity and our capability to produce specialized, high-value medicines that meet the most stringent international standards. It's a key milestone in our mission to not only serve the needs of the Pakistani market but also to become a recognized partner in global healthcare.
No results!